A special focus of the report is the bustle of activity with collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs. This report profiles scores of such companies operating in this market and estimates and forecasts markets (where there are products on the market) for personalized medicine technologies in the following categories:
• Cardiac Markers, immunoassays
• Cardiac Risk Markers
• Cardiac markers, molecular
• Coagulation, routine
• Coagulation, molecular
• Cancer, Tumor Markers
• Cancer, Molecular
• Cancer, Tissue-based
• Psychiatric Disorders
• Diabetes, BGM
• Diabetes, HbA1c
• Microbiology, ID/AST
• Infectious Diseases, Viral Load (HIV, HCV, HBV)
• Infectious Diseases, other
• Blood Bank Molecular
• Transplant Tissue Typing
• Lab Developed Tests
No. of Pages: 430
Price: Single User License – US$3795 Corporate User License – US$7590
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.
Developments that are linked in the press to 'personalized medicine' are many, and can at times be confusing. But there are several discovered biomarkers that are important in diagnostic markets.
Biomarkers discussed in the report include:
• Cytochrome P450 and Drug Metabolism
• Estrogen Receptor and Progesterone
• Receptor Status for Breast Cancer
• HER2 Overexpression and Herceptin and Tykerb
• Epidermal Growth Factor Receptor (EGFR)
• KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
• BRAF Mutations and Cancer Therapy
• UGT1A1 Genetic Variants
• 5-Flurouracil Therapy
• PIK3CA Genetic Variation
• KIF6 Genetic Variation
• ALK Genetic Variation
Major points covered in Table of Contents of this report include:
• CHAPTER ONE: EXECUTIVE SUMMARY
• CHAPTER TWO: INTRODUCTION
• CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”
• CHAPTER FOUR: DISEASE TARGETS
• CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES
• CHAPTER SIX: MARKET ANALYSIS
• CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
• CHAPTER EIGHT: COMPANY PROFILES
• List of Tables
Explore Reports related to Biotechnology @ http://www.reportsnreports.com/market-research/biotechnology/
• Cardiac Markers, immunoassays
• Cardiac Risk Markers
• Cardiac markers, molecular
• Coagulation, routine
• Coagulation, molecular
• Cancer, Tumor Markers
• Cancer, Molecular
• Cancer, Tissue-based
• Psychiatric Disorders
• Diabetes, BGM
• Diabetes, HbA1c
• Microbiology, ID/AST
• Infectious Diseases, Viral Load (HIV, HCV, HBV)
• Infectious Diseases, other
• Blood Bank Molecular
• Transplant Tissue Typing
• Lab Developed Tests
Global Personalized Medicine Diagnostics Market
Published: March 2012No. of Pages: 430
Price: Single User License – US$3795 Corporate User License – US$7590
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.
Developments that are linked in the press to 'personalized medicine' are many, and can at times be confusing. But there are several discovered biomarkers that are important in diagnostic markets.
Biomarkers discussed in the report include:
• Cytochrome P450 and Drug Metabolism
• Estrogen Receptor and Progesterone
• Receptor Status for Breast Cancer
• HER2 Overexpression and Herceptin and Tykerb
• Epidermal Growth Factor Receptor (EGFR)
• KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
• BRAF Mutations and Cancer Therapy
• UGT1A1 Genetic Variants
• 5-Flurouracil Therapy
• PIK3CA Genetic Variation
• KIF6 Genetic Variation
• ALK Genetic Variation
Major points covered in Table of Contents of this report include:
• CHAPTER ONE: EXECUTIVE SUMMARY
• CHAPTER TWO: INTRODUCTION
• CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”
• CHAPTER FOUR: DISEASE TARGETS
• CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES
• CHAPTER SIX: MARKET ANALYSIS
• CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
• CHAPTER EIGHT: COMPANY PROFILES
• List of Tables
Explore Reports related to Biotechnology @ http://www.reportsnreports.com/market-research/biotechnology/
No comments:
Post a Comment